Abbott today announces it has received 510(k) clearance from the FDA for its new, compact hematology instrument, CELL-DYN Emerald™.
Abbott’s CELL-DYN Emerald will expand the company’s hematology platform by offering a high performance, affordable solution for small to mid-sized clinical laboratories.
As small to mid-sized hospital laboratories and clinics continue to seek greater efficiency and productivity under tighter space limitations, Emerald’s small size, touch screen software, and reliability offer a compact table/bench top instrument for performing complete blood counts (CBCs), a test routinely ordered by doctors to assess a patient’s overall health and to screen for a variety of disorders such as anemia and infection.
This new hematology system has many automation features designed to save laboratories’ time, allowing them to improve productivity and reduce costs.
CELL-DYN Emerald features a compact size — it weighs just 9kg (< 20 lbs) — as well as its intuitive software interface that allows for easy navigation and quick results. With Abbott’s Emerald, CBC results are completed in 60 seconds and reported in an easy-to-read format with histograms representing white blood cells, red blood cells, and platelets.
"As hospitals and clinics try to do more, faster and in less space, Abbott’s CELL-DYN Emerald offers a compact, fast, reliable analyzer to support the hematology testing needs of many small to medium-sized hospital laboratories and clinics," said Mike Warmuth, senior vice president, diagnostics, Abbott.
